Loucia Kit Ying Chan

Loucia Kit Ying Chan

Auto-generated profile, based on publicly available information

Loucia Kit Ying Chan

Department of Obstetrics and Gynaecology, Chinese University of Hong Kong

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
HLHo Sze Jacqueline Lee
Ho Sze Jacqueline Lee
Joseph KwongJoseph Kwong
Joseph Kwong
Emerging evidence shows that the efficacy of chemotherapeutic drugs is reliant on their capability to induce immunogenic cell death (ICD), thus transforming dying tumor cells into antitumor vaccines. We wanted to uncover potential therapeutic strategies that target ovarian cancer by having a better understanding of the standard-of-care chemotherapy treatment. Here, we showed in ovarian cancer that paclitaxel induced ICD-associated damage-associated molecular patterns (DAMP, such as CALR exposure, ATP secretion, and HMGB1 release) in vitro and elicited significant antitumor responses in tumor vaccination assays in vivo. Paclitaxel-induced TLR4 signaling was essential to the release of DAMPs, which led to the activation of NF-κB–mediated CCL2 transcription and IkappaB kinase 2–mediated SNARE-dependent vesicle exocytosis, thus exposing CALR on the cell surface. Paclitaxel induced endoplasmic reticulum stress, which triggered protein kinase R–like ER kinase activation and eukaryotic translation initiation factor 2α phosphorylation independent of TLR4. Paclitaxel chemotherapy induced T-cell infiltration in ovarian tumors of the responsive patients; CALR expression in primary ovarian tumors also correlated with patients' survival and patient response to chemotherapy. These findings suggest that the effectiveness of paclitaxel relied upon the activation of antitumor immunity through ICD via TLR4 and highlighted the importance of CALR expression in cancer cells as an indicator of response to paclitaxel chemotherapy in ovarian cancer.

4 April 2023
Verified
Other
Open access
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
JLJacqueline Ho Sze Lee
Jacqueline Ho Sze Lee
JKJoseph Kwong
Joseph Kwong
All Supplementary Figures and their respective legends.

4 April 2023
Verified
Other
Open access
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
JLJacqueline Ho Sze Lee
Jacqueline Ho Sze Lee
JKJoseph Kwong
Joseph Kwong
Emerging evidence shows that the efficacy of chemotherapeutic drugs is reliant on their capability to induce immunogenic cell death (ICD), thus transforming dying tumor cells into antitumor vaccines. We wanted to uncover potential therapeutic strategies that target ovarian cancer by having a better understanding of the standard-of-care chemotherapy treatment. Here, we showed in ovarian cancer that paclitaxel induced ICD-associated damage-associated molecular patterns (DAMP, such as CALR exposure, ATP secretion, and HMGB1 release) in vitro and elicited significant antitumor responses in tumor vaccination assays in vivo. Paclitaxel-induced TLR4 signaling was essential to the release of DAMPs, which led to the activation of NF-κB–mediated CCL2 transcription and IkappaB kinase 2–mediated SNARE-dependent vesicle exocytosis, thus exposing CALR on the cell surface. Paclitaxel induced endoplasmic reticulum stress, which triggered protein kinase R–like ER kinase activation and eukaryotic translation initiation factor 2α phosphorylation independent of TLR4. Paclitaxel chemotherapy induced T-cell infiltration in ovarian tumors of the responsive patients; CALR expression in primary ovarian tumors also correlated with patients' survival and patient response to chemotherapy. These findings suggest that the effectiveness of paclitaxel relied upon the activation of antitumor immunity through ICD via TLR4 and highlighted the importance of CALR expression in cancer cells as an indicator of response to paclitaxel chemotherapy in ovarian cancer.

4 April 2023
Verified
Other
Open access
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
JLJacqueline Ho Sze Lee
Jacqueline Ho Sze Lee
JKJoseph Kwong
Joseph Kwong

4 April 2023
Verified
Other
Open access
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
JLJacqueline Ho Sze Lee
Jacqueline Ho Sze Lee
JKJoseph Kwong
Joseph Kwong
Emerging evidence shows that the efficacy of chemotherapeutic drugs is reliant on their capability to induce immunogenic cell death (ICD), thus transforming dying tumor cells into antitumor vaccines. We wanted to uncover potential therapeutic strategies that target ovarian cancer by having a better understanding of the standard-of-care chemotherapy treatment. Here, we showed in ovarian cancer that paclitaxel induced ICD-associated damage-associated molecular patterns (DAMP, such as CALR exposure, ATP secretion, and HMGB1 release) in vitro and elicited significant antitumor responses in tumor vaccination assays in vivo. Paclitaxel-induced TLR4 signaling was essential to the release of DAMPs, which led to the activation of NF-κB–mediated CCL2 transcription and IkappaB kinase 2–mediated SNARE-dependent vesicle exocytosis, thus exposing CALR on the cell surface. Paclitaxel induced endoplasmic reticulum stress, which triggered protein kinase R–like ER kinase activation and eukaryotic translation initiation factor 2α phosphorylation independent of TLR4. Paclitaxel chemotherapy induced T-cell infiltration in ovarian tumors of the responsive patients; CALR expression in primary ovarian tumors also correlated with patients' survival and patient response to chemotherapy. These findings suggest that the effectiveness of paclitaxel relied upon the activation of antitumor immunity through ICD via TLR4 and highlighted the importance of CALR expression in cancer cells as an indicator of response to paclitaxel chemotherapy in ovarian cancer.

4 April 2023
Verified
Other
Open access
TLTat San Lau
Tat San Lau
LCLoucia Kit Ying Chan
Loucia Kit Ying Chan
CMChi Wai Man
Chi Wai Man
CWChi Hang Wong
Chi Hang Wong
JLJacqueline Ho Sze Lee
Jacqueline Ho Sze Lee
JKJoseph Kwong
Joseph Kwong